T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

NEXT STORY
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PREV STORY
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

- Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for ...

author_avatar
NASDAQ Market News

BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA

author_avatar
NASDAQ Market News

Inovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017

PLYMOUTH MEETING, Pa., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced ...

author_avatar
NASDAQ Market News